As of Mar 27, 2024, the VRTX stock has a PE ratio of 29.7. The calculation is based on the latest EPS of $14.05 and the stock price of $417.32 per share. An increase of 12% has been observed in the PE ratio compared to its average of 26.6 of the past four quarters.
The mean historical PE ratio of Vertex Pharmaceuticals over the last seven years is 54.22. The current 29.7 price-to-earnings ratio is 45% less than the historical average. Analyzing the last seven years, VRTX's PE ratio reached its highest point in the Sep 2017 quarter at 190.05, with a price of $152.04 and an EPS of $0.8. The Dec 2018 quarter saw the lowest point at 20.11, with a price of $165.71 and an EPS of $8.24.
Maximum annual increase: 137.74% in 2019
Maximum annual decrease: -85.78% in 2018
Year | PE ratio | Change |
---|---|---|
2023 | 28.96 | 30.04% |
2022 | 22.27 | -7.82% |
2021 | 24.16 | 6.71% |
2020 | 22.64 | -52.65% |
2019 | 47.81 | 137.74% |
2018 | 20.11 | -85.78% |
2017 | 141.38 | N/A |
2016 | N/A | N/A |
2015 | N/A | N/A |
2014 | N/A | N/A |
VRTX's current PE ratio is higher than the 3 and 5-year averages, but it is under its 10-year average.
When compared to its peers MRK and ABBV, VRTX's PE ratio is lower, but it is higher than JNJ's and BMY's. Vertex Pharmaceuticals is currently trading at a higher PE ratio (29.7) than its peers average of 21.5.
Stock name | PE ratio | Market cap |
---|---|---|
ENZN Enzon Pharmaceuticals Inc | 0.26 | $4.18M |
JNJ Johnson & Johnson | 11.41 | $381.58B |
BMY Bristol Myers Squibb Co | 13.84 | $108.57B |
GILD Gilead Sciences Inc | 16.17 | $91.43B |
VRTX Vertex Pharmaceuticals Inc | 29.83 | $108.25B |
ABBV AbbVie Inc | 66.29 | $319.67B |
MRK Merck & Co Inc | 939.57 | $333.14B |
ENTA Enanta Pharmaceuticals Inc | N/A | $350.45M |
The price to earnings ratio for VRTX stock is 29.7 as of Mar 27, 2024.
Over the last 3 years, the average PE ratio for VRTX stock is 24.45.
Over the last 5 years, the average PE ratio for VRTX stock is 26.5.
The highest quarterly PE ratio in the last seven years has been 190.05 and it was in the Sep 2017 quarter.
VRTX's current price to earnings ratio is 45% below its 7-year historical average.
The P/E ratio is calculated by taking the latest stock price and dividing it by the earnings per share(EPS) for the last 12 months. As of today (Mar 27, 2024), Vertex Pharmaceuticals's share price is $417.32. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2023 is $14.05. Therefore, Vertex Pharmaceuticals's price to earnings ratio for today is 29.7. PE RATIO(29.7) = STOCK PRICE($417.32) / TTM EPS($14.05)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified.